Deprenyl And 'Excess Mortality'

Monoamine oxidase B inhibitors. Current status and future potential

The effect of L-deprenyl on spatial short term memory in young and aged dogs

Effects of selegiline (deprenyl) on cognition in early Parkinson's disease

Rationale for (-)-deprenyl (Selegiline) therapy in Parkinson's disease and Alzheimer's disease

Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes

Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus

Therapy with l-deprenyl (selegiline) and relation to abuse liability

The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats

The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases

An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease

Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases

(-)Deprenyl-medication: A strategy to modulate the age-related decline of the striatal dopaminergic system

Monoamine oxidase inhibitors: Reversible and irreversible

The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: A personal view

L-deprenyl therapy improves verbal memory in amnesic alzheimer patients

A pilot study of low-dose L-deprenyl in Alzheimer's disease

Potential applications for monoamine oxidase B inhibitors

Monoamine oxidase and dementia: Treatment with an inhibitor of MAO-B activity

Neuropsychological effects of L-deprenyl in Alzheimer's type dementia

The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid

Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma

Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior

Brief information on an early phase-II-study with deprenyl in demented patients

L-Deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition

Cognitive effects of L-deprenyl in Alzheimer's disease

Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: Electrophysiological studies in the rat central nervous system

Tyramine pressor sensitivity changes during deprenyl treatment

The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence

l-Deprenyl in atypical depressives

The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment

Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease

Deprenyl (selegiline) in combination treatment of Parkinson's disease

L-deprenyl plus L-phenylalanine in the treatment of depression

L-deprenyl, a selective monoamine oxidase type-b inhibitor in endogenous depression

Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats

Deprenyl in Parkinson's disease

The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats

Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system

Selegiline in the treatment of behavioural disturbance in Alzheimer's disease

Deprenyl in the treatment of Parkinson's disease: Clinical effects and speculations on mechanism of action

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration

L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro

The natural history of Parkinson's disease

Effect of lazabemide on the progression of disability in early Parkinson's disease

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa

New approaches to drug treatment of Parkinson's disease

Novel sites of action for deprenyl in MPTP-parkinsonism: Metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice

Combined treatment in Parkinson's disease

In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striataI L-DOPA and dopamine metabolism

Selegiline: A review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease

Combined treatment in Parkinson's disease

Treatment of Parkinson's disease

Clinical pharmacokinetics of drugs for Alzheimer's disease

Anticonvulsant and antiepileptogenic effect of L-deprenyl (selegiline) in the kindling model of epilepsy

Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats

What is it that l-deprenyl (selegiline) might do?

Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal

Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons

Effect of L-Deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake

Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism

Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat

Monoamine oxidase (MAO): Relationships to foods, poisons and medicines

Deprenyl increases survival of rat foetal nigral neurones in culture

Chronic treatment of aged mice with L-deprenyl produces marked striatal MAO-B inhibition but no beneficial effects on survival, motor performance, or nigral lipofuscin accumulation

Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease

Parkinson's disease: Past, present, and future

Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: A quantitative assessment

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: Suppression by clorgyline and deprenyl

Neurotoxicity of levodopa on catecholamine-rich neurons

A review of the pharmacology of selegiline

Parkinson's disease: An epidemiologic method for distinguishing between symptomatic and neuroprotective treatments

L-Deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease

New approaches in the use of selegiline for the treatment of Parkinson's disease

Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: A double-blind cross-over placebo-controlled trial

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial

Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline)

Problems associated with long-term levodopa treatment of Parkinson's disease

Overview of present day treatment of Parkinson's disease

The possible mechanisms of action of (-)deprenyl in Parkinson's disease